CompletedPhase 1

Definitive QT Study With MT-8554

United Kingdom48 participantsStarted 2018-04-23

Plain-language summary

This is a study to definitively assess the effects of MT 8554, adjusted for placebo, on the change of the QT interval corrected for heart rate (HR) using the Fridericia formula (QTcF) from Baseline in healthy adult subjects

Who can participate

Age range18 Years – 55 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Inflammatory bowel syndrome, gastritis, ulcers, GI or rectal bleeding
✕. Major GI surgery such as gastrectomy, gastroenterostomy, or bowel resection
✕. Clinical evidence of pancreatic injury or pancreatitis

What they're measuring

Change from baseline in QTcF with placebo adjustment

Timeframe: Days 1 & 7

Trial details

NCT IDNCT03471130

SponsorTanabe Pharma America, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2018-10-19

View on ClinicalTrials.gov More Healthy Volunteer trials